title: Proliferative tumor doubling times of prostatic carcinoma.
abstract: Prostate cancer (PCa) has a variable biology ranging from latent cancer to extremely aggressive tumors. Proliferative activities of cancers may indicate their biological potential. A flow cytometric assay to calculate maximum proliferative doubling times (T(max)) of PCa in radical prostatectomy specimens after preoperative in vivo bromodeoxyuridine (BrdU) infusion is presented. Only 4/17 specimens had tumors large enough for flow cytometric analysis. The T(max) of tumors was similar and ranged from 0.6 to 3.6 months. Tumors had calculated doubling times 2- to 25-fold faster than their matched normal tissue. Variations in labeling index and T(max) were observed within a tumor as well as between different Gleason grades. The observed PSA doubling times (PSA-DT) ranged from 18.4 to 32.0 months, considerably slower than the corresponding T(max) of tumors involved. While lack of data for apoptotic rates is a limitation, apparent biological differences between latent versus aggressive PCa may be attributable to variations in apoptotic rates of these tumors rather than their cell proliferative rates.
authors.affiliation: Department of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USA.
authors.forename: Priya N
authors.initials: PN
authors.lastname: Werahera
authors.forename: L Michael
authors.initials: LM
authors.lastname: Glode
authors.forename: Francisco G
authors.initials: FG
authors.lastname: La Rosa
authors.forename: M Scott
authors.initials: MS
authors.lastname: Lucia
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.forename: Kenneth
authors.initials: K
authors.lastname: Easterday
authors.forename: Holly T
authors.initials: HT
authors.lastname: Sullivan
authors.forename: Rameshwar S
authors.initials: RS
authors.lastname: Sidhu
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Genova
authors.forename: Tammy
authors.initials: T
authors.lastname: Hedlund
references.citation: Urology. 1981 Mar;17(Suppl 3):40-53
references.pmid: 7010755
references.citation: Cancer. 1993 Mar 15;71(6):2031-40
references.pmid: 7680277
references.citation: Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1067-70
references.pmid: 9169814
references.citation: Eur Urol. 1993;23 Suppl 2:60-3
references.pmid: 7685704
references.citation: J Urol. 1994 Nov;152(5 Pt 2):1709-13
references.pmid: 7933231
references.citation: In Vivo. 1994 May-Jun;8(3):439-43
references.pmid: 7803731
references.citation: Cancer Prev Res (Phila). 2008 Aug;1(3):167-73
references.pmid: 19138952
references.citation: J Urol. 1974 Jan;111(1):58-64
references.pmid: 4813554
references.citation: Hum Pathol. 2004 Jul;35(7):798-807
references.pmid: 15257542
references.citation: Cancer. 2006 Mar 1;106(5):1047-53
references.pmid: 16456812
references.citation: J Urol. 1998 Apr;159(4):1260-4
references.pmid: 9507848
references.citation: Jpn J Clin Oncol. 2011 Apr;41(4):555-64
references.pmid: 21233104
references.citation: J Urol. 1998 Apr;159(4):1265-9
references.pmid: 9507849
references.citation: Monogr Pathol. 1992;(34):183-97
references.pmid: 1406741
references.citation: Cytometry. 1985 Nov;6(6):620-6
references.pmid: 4064842
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: J Urol. 1989 Feb;141(2):337-40
references.pmid: 2643726
references.citation: Drug News Perspect. 2010 Apr;23(3):185-94
references.pmid: 20440420